瑞德西韦在COVID-19治疗中的综述
瑞德西韦是一种具有广谱抗病毒活性的核苷酸类似物前药,获批用于治疗COVID-19。关键ACTT-1试验显示,住院患者每日静脉输注瑞德西韦较安慰剂显著缩短恢复时间;后续试验支持其在住院中重度患者中的疗效,基线需氧量最低者获益更大。门诊高风险患者及住院儿科患者亦显示有效。死亡率结果不一,但基线未通气住院患者可能有小幅生存获益。真实世界药物警戒数据显示肝、肾及心血管不良反应风险增加。
要点
- 瑞德西韦每日静脉输注(通常5–10天)可缩短住院COVID-19患者恢复时间
- 基线需氧量最低者及未通气患者获益更明显,死亡率获益不确定
- 门诊高风险患者3天疗程有效,住院儿科患者亦显示疗效
核心结论
- 瑞德西韦是COVID-19患者的有用治疗选择,尤其需要补充氧气的患者。
研究设计与样本
- 综述基于关键ACTT-1试验及后续临床试验,涵盖住院、门诊及儿科患者。
主要发现
- ACTT-1试验中住院患者每日静脉输注瑞德西韦较安慰剂显著缩短恢复时间。
- 后续试验支持住院中重度COVID-19疗效,基线需氧量最低者获益更大。
- 门诊高风险进展为重症患者及住院儿科患者亦显示疗效。
- 死亡率结果不一,基线未通气住院患者可能有小幅死亡获益。
- 临床试验耐受性一般良好,真实世界药物警戒发现肝、肾及心血管不良反应风险增加。
关键数值与推荐
- 瑞德西韦通常每日一次静脉输注,疗程5–10天;门诊高风险患者3天疗程有效。
- 药物相互作用潜力低。
临床怎么用
- 用于住院COVID-19患者,尤其需要补充氧气者,可缩短恢复时间。
- 门诊高风险患者可考虑3天疗程。
- 用药期间关注肝、肾及心血管不良反应。
局限性
- 死亡率结果不一,获益不确定。
- 真实世界安全性数据提示肝、肾及心血管不良反应风险增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Remdesivir (Veklury®), a nucleotide analogue prodrug with broad-spectrum antiviral activity, is approved for the treatment of coronavirus disease 2019 (COVID-19), the illness caused by severe acute respiratory syndrome coronavirus 2 infection. Unlike some antivirals, remdesivir has a low potential for drug-drug interactions. In the pivotal ACTT-1 trial in hospitalized patients with COVID-19, daily intravenous infusions of remdesivir significantly reduced time to recovery relative to placebo. Subsequent trials provided additional support for the efficacy of remdesivir in hospitalized patients with moderate or severe COVID-19, with a greater benefit seen in patients with minimal oxygen requirements at baseline. Clinical trials also demonstrated the efficacy of remdesivir in other patient populations, including outpatients at high risk for progression to severe COVID-19, as well as hospitalized paediatric patients. In terms of mortality, results were equivocal. However, remdesivir appeared to have a small mortality benefit in hospitalized patients who were not already being ventilated at baseline. Remdesivir was generally well tolerated in clinical trials, but pharmacovigilance data found an increased risk of hepatic, renal and cardiovascular adverse drug reactions in the real-world setting. In conclusion, remdesivir represents a useful treatment option for patients with COVID-19, particularly those who require supplemental oxygen. Coronavirus disease 2019 (COVID-19) was first reported in China in 2019 and quickly spread around the world. The symptoms of COVID-19 can vary from person to person, with some people having no symptoms and others becoming very unwell. Most patients with COVID-19 can treat their symptoms at home, but some patients may be admitted to hospital and/or treated with specialized medications such as remdesivir (Veklury®). Remdesivir is an antiviral medicine that can reduce the amount of virus that causes COVID-19. It is given once a day, usually for 5–10 days, as an intravenous infusion. Remdesivir has been shown to improve the recovery time in hospitalized patients with COVID-19, including children and adolescents. It may also reduce the risk of death in hospitalized patients who are not being ventilated before they start treatment. A 3-day course of remdesivir is also effective in patients whose age or underlying health puts them at high risk for becoming severely ill. The drug is generally well tolerated. Therefore, remdesivir is a useful treatment option for patients with COVID-19, especially those who require additional oxygen.
引用
- Blair HA. Remdesivir: A Review in COVID-19. Drugs. 2023. PMID: 37589788. doi:10.1007/s40265-023-01926-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。